Want to create an interactive transcript for this episode?
Podcast: Australian Investors Podcast
Episode: Inside NEU: The ASX pharma star with a long runway for growth
Description: Jump back to 2021 and Neuren Pharmaceuticals Ltd (ASX: NEU) share price consistently traded around $1.50 and occasionally breached $2. Within three years it would hit a high of $25 a share. NEU received FDA approval for a drug called Trofenetide, a drug which treats a rare syndrome called Rett Syndrome. With a drug on the shelves in the US, NEU now has the cashflows to self-fund the next leg of growth.
In this Australian Investors Podcast episode, your host Mitchell Sneddon sits down with Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX: NEU) to discuss:
– The impact of trofinetide on Rett syndrome patients an...